Total Marrow Irradiation Combined with High-Dose Melphalan for Patients with Relapsed/Refractory Multiple Myeloma: A Phase 1 Study

High dose melphalan at 200  mg/m2 (Mel200) followed by autologous stem cell transplant (ASCT) improves progression free survival in patients with multiple myeloma (MM) but is not curative. Enhancing the anti-myeloma effect of pre-transplant conditioning without increasing toxicity is therefore an important goal. With this r ationale, intensity modulated radiation therapy (IMRT) can be used to deliver a high dose of radiation to the bone marrow (total marrow irradiation, TMI) while sparing other organs.

Source: Biology of Blood and Marrow Transplantation - February 22, 2017 Category: Hematology Authors: Pritesh Rajni Patel, Annie Oh, Matthew Koshy, Karen Sweiss, Santosh Saraf, John Quigley, Irum Khan, Nadim Mahmud, Eileen Danaher Hacker, Howard Ozer, David Peace, Ralph R. Weichselbaum, Bulent Aydogan, Damiano Rondelli Source Type: research